LDS/Medical Tests/TERT (Telomerase Reverse Transcriptase) Gene Mutation Analysis

TERT (Telomerase Reverse Transcriptase) Gene Mutation Analysis

The TERT gene is located on the short (p) arm of chromosome 5 at position 15.33 and encodes telomerase reverse transcriptase (TERT). This protein contains four conserved structural domains: the telomerase essential N-terminal (TEN) domain, the telomerase RNA binding domain (TRBD), the reverse transcriptase (RT) domain and the C-terminal extension (CTE) domain. TERT protein, which has a reverse transcriptase activity, is a catalytic subunit of the enzyme telomerase. Telomerase is an enzyme complex that can extend the length of telomeres, thus helping to slow the shortening process involved in cell senescence. Telomeres are composed of TTAGGG nucleotide repeats at each end of chromosomes that protect the chromosome from deterioration or fusion to other chromosomes. In human telomeres TTAGGG is repeated about 2500 times at birth but the length of the repeats decreases with age. Variants in TERT and other genes involved with telomere repair and maintenance may cause telomeres to shorten more quickly than normal leading to early cell death. Telomerase may also be abnormally active in most cancer cells, allowing them to grow and survive. Mutations in TERT are associated with dyskeratosis congenita, idiopathic pulmonary fibrosis, melanoma and acute myeloid leukemia.

Dyskeratosis congenita (DC) is characterized by a classic triad of dysplastic nails, lacy reticular pigmentation of the upper chest and/or neck, and oral leukoplakia. People with DC are at increased risk for progressive bone marrow failure, myelodysplastic syndromes (MDS), acute myelogenous leukemia (AML), solid tumors and pulmonary fibrosis. Other findings can include abnormal pigmentation changes not restricted to the upper chest and neck, eye abnormalities (epiphora, blepharitis, sparse eyelashes, ectropion, entropion, trichiasis), and dental abnormalities (caries, periodontal disease, taurodauntism). Most of the TERT gene mutations that cause dyskeratosis congenita change single amino acids in the TERT protein, causing it to be unstable or dysfunctional. The mutations interfere with telomerase function, leading to impaired maintenance of telomeres and reduced telomere length. Cells that divide rapidly are especially vulnerable to the effects of shortened telomeres. As a result, people with dyskeratosis congenita may experience a variety of problems affecting quickly dividing cells in the body such as cells of the nail beds, hair follicles, skin, lining of the mouth (oral mucosa), and bone marrow. Breakage and instability of chromosomes resulting from inadequate telomere maintenance may lead to genetic changes that allow cells to divide in an uncontrolled way, resulting in the development of cancer in some people with dyskeratosis congenita. Hoyeraal Hreidarsson syndrome and Revesz syndrome are two forms of DC with more severe manifestations.

Some cases of ‘Idiopathic’ pulmonary fibrosis (IPF) are due to mutations in the TERT gene that reduce or eliminate the function of telomerase. Lack of telomerase activity in alveolar lining cells, likely triggers them to stop dividing or to die prematurely resulting in alveolar fibrosis. Most cases are familial although sporadic cases are reported.

Mutations in the TERT gene have also been associated with an increased risk of various cancers, in particular melanoma and acute myeloid leukemia. These mutations may impair telomere maintenance and result in DNA damage. Damage to genes that help control the growth and development of cells can cause uncontrolled cell growth and lead to the development of these cancers.

Approximately 34% of individuals with a central nervous system (CNS) tumor have a somatic mutation in the TERT gene. TERT promoter mutations have been described highest frequencies in oligodendroglioma, primary glioblastoma, solitary fibrous tumor/ haemangiopericytoma and medulloblastoma.

  • Diagnostic confirmation of TERT-associated dyskeratosis congenital
  • As an aid in diagnosis of idiopathic pulmonary fibrosis
  • As an aid in diagnosis and management of central nervous system (CNS) tumors
  • Used as a part of cancer panel for diagnosis of breast cancer, cholangiocarcinoma, melanoma, and neural cancers
  • For the carrier testing for family members of the affected patient
  • For the prenatal diagnosis in at-risk pregnancies
Mutation or pathogenic variant in TERT gene are supportive of diagnosis. Pathogenic variants may include small intragenic deletions/insertions and missense, nonsense, and splice site variants.

No reportable alterations were identified in the targeted of the TERT gene

Sequence analysis by next generation sequencing or bi-directional sequencing. TERT gene-targeted deletion/duplication analysis detects intragenic deletions or duplications. Methods that may be used include quantitative PCR, long-range PCR, multiplex ligation-dependent probe amplification (MLPA), targeted array CGH (comparative genomic hybridization) analysis and a gene-targeted microarray designed to detect single-exon deletions or duplications.

Whole blood, Blood spot, Peripheral blood mononuclear cells (PBMCs), Cultured fibroblasts, Skin biopsy, Formalin-Fixed, Paraffin-Embedded tissue (FFPE).

Stability

Blood and cultured cells

  • Ambient: 3-5 days
  • Refrigerated: 7-14 days
  • FFPE is stable at room indefinitely
Telomere Defects Gene Panel, pathogenic variants analysis in ACD, PARN, CTC1, DKC1, NHP2, NOP10, RTEL1, TERC, TERT, TINF2, USB1 (C16ORF57), and WRAP53 (TCAB1) genes, bone marrow biopsy, multicolor flow cytometry fluorescence in situ hybridization (flow-FISH).
1-2 weeks.
Please log in to view content.
Create an account to get a 30-day free trial.
Login
Please log in to view content.
Create an account to get a 30-day free trial.
Login
Please log in to view content.
Create an account to get a 30-day free trial.
Login